U.S. markets closed

Bolt Biotherapeutics, Inc. (BOLT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
9.04-0.06 (-0.66%)
At close: 1:00PM EST
9.04 0.00 (0.00%)
After hours: 02:29PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Relative Strength Index (RSI)

Relative Strength Index (RSI)

Previous Close9.10
Bid7.60 x 3200
Ask9.74 x 1800
Day's Range8.77 - 9.13
52 Week Range7.58 - 43.07
Avg. Volume208,684
Market Cap337.053M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-4.20
Earnings DateNov 09, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est39.80
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for BOLT

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Bolt Biotherapeutics, Inc.
    Daily – Vickers Top Buyers & Sellers for 02/12/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    9 months agoArgus Research
View more
  • GlobeNewswire

    Bolt Biotherapeutics Announces Changes to its Board of Directors

    REDWOOD CITY, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today announced the appointments of Brian O’Callaghan and Frank D. Lee to the Board of Directors. With these additions, longtime Director Peter Moldt, Ph.D. is stepping down from the Board of Directors and

  • GlobeNewswire

    Bolt Biotherapeutics Presents New Preclinical Data on Three Pipeline Programs at Society for Immunotherapy of Cancer (SITC) Annual Meeting

    Presentation of preclinical data supporting the selection of BDC-2034, an ISAC targeting CEA, as Bolt Biotherapeutics’ second Boltbody™ ISAC development candidateDemonstration of the novel, multifunctional mechanism for an ISAC which combines PD-1/PD-L1 axis inhibition with TLR agonismIdentification of novel agonist antibodies targeting Dectin-2, now revealed as Bolt Biotherapeutics’ TAM1 target, designed to reprogram tumor-supportive macrophages into tumor-destructive macrophages REDWOOD CITY,

  • GlobeNewswire

    Bolt Biotherapeutics Reports Third Quarter 2021 Financial Results and Provides Business Highlights

    –BDC-1001 Phase 1/2 dose-escalation interim clinical trial update in HER2-expressing solid tumors to be presented at ESMO Immuno-Oncology Congress 2021–Strong cash position of $295.5 million expected to fund operations through the end of 2023 REDWOOD CITY, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of bo